Lake Street analyst Chad Messer lowered the firm's price target on Oncolytics to $5 from $7 and keeps a Buy rating on the shares after the company reported FY25 results and announced it has scheduled a Type C meeting with the FDA for April 16 to align on the design of a single-arm pivotal study for pelareorep in squamous cell anal carcinoma.